Related Experiment Video
Updated: Jul 25, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Targeted Therapies and Developing Precision Medicine in Gastric Cancer
Rille Pihlak1, Caroline Fong1, Naureen Starling1
1Gastrointestinal/Lymphoma Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
Abstract:
Gastric cancer is an aggressive disease with survival remaining poor in the advanced setting. More than a decade after the first targeted treatment was approved, still only HER2, MSI and PDL-1 status have reached everyday practice in terms of guiding treatment options for these patients. However, various new targets and novel treatments have recently been investigated and have shown promise in improving survival outcomes. In this review, we will summarise previous and currently ongoing studies on predictive biomarkers, possible new targeted treatments, potential reasons for conflicting trial results and hope for the future of precision medicine in gastric cancer.
Insights
Gastric cancer survival remains poor, but new targeted treatments and predictive biomarkers show promise. Precision medicine offers hope for improved outcomes in advanced stages.
Area of Science:
- Oncology
- Gastroenterology
- Pharmacology
Background:
- Gastric cancer has a poor prognosis, especially in advanced stages.
- Current targeted treatments are limited to HER2, MSI, and PD-L1 status.
- Despite advances, effective treatment strategies for many patients are lacking.
Purpose of the Study:
- To review predictive biomarkers for gastric cancer.
- To summarize novel targeted treatments under investigation.
- To explore reasons for conflicting clinical trial results and future directions in precision medicine.
Main Methods:
- Literature review of previous and ongoing studies.
- Analysis of predictive biomarkers and targeted therapies.
- Discussion of clinical trial outcomes and challenges.
Main Results:
- HER2, MSI, and PD-L1 are established predictive biomarkers.
- Emerging biomarkers and targeted agents show potential for improved survival.
- Conflicting trial results highlight the complexity of gastric cancer treatment.
Conclusions:
- Precision medicine holds significant promise for advancing gastric cancer care.
- Further research into novel biomarkers and treatments is crucial.
- Personalized therapeutic strategies are key to improving patient outcomes.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Mitogens and the Cell Cycle
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

